Patents by Inventor Zihe Rao

Zihe Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240360459
    Abstract: The present disclosure provides a Mycobacterium tuberculosis (Mtb) adenosine triphosphate (ATP) synthase-expressing recombinant bacterium, and a construction method and an expression method thereof, and belongs to the technical field of exogenous expression. The present disclosure provides a construction method of an Mtb ATP synthase-expressing recombinant bacterium, including the following steps: using a Mycobacterium smegmatis (Msm) competent cell containing an auxiliary gene knockout plasmid as a basal cell; transferring an Mtb ATP synthase gene cluster with an affinity purification tag into the basal cell, knocking out a Msm ATP synthase genome, and collecting a strain without the auxiliary gene knockout plasmid after conducting repeated subculture; and transferring the Mtb ATP synthase gene cluster into the strain by prokaryotic expression to obtain the Mtb ATP synthase-expressing recombinant bacterium.
    Type: Application
    Filed: February 9, 2024
    Publication date: October 31, 2024
    Inventors: Hongri Gong, Yuying Zhang, Zihe Rao
  • Publication number: 20230302019
    Abstract: Disclosed is compound YM155, tanshinone I or cryptotanshinone, or a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof; for treating and/or preventing diseases caused by coronavirus.
    Type: Application
    Filed: April 29, 2021
    Publication date: September 28, 2023
    Inventors: Haitao YANG, Zhenming JIN, Xiaoyu DU, Yinkai DUAN, Yao ZHAO, Xiuna YANG, Zihe RAO
  • Publication number: 20230293457
    Abstract: An application of disulfiram in coronavirus resistance. An application of disulfiram in the preparation of drugs for treating and/or preventing diseases caused by coronaviruses. By means of in vitro enzyme activity experiments, it is found that disulfiram can well inhibit the activity of the main protease in coronaviruses, filling in the lack in the prior art to treat diseases caused by coronaviruses.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 21, 2023
    Inventors: Haitao YANG, Zhenming JIN, Xiuna YANG, Yao ZHAO, Zihe RAO
  • Patent number: 11655238
    Abstract: The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: May 23, 2023
    Assignee: SHANGHAITECH UNIVERSITY
    Inventors: Zihe Rao, Jun Li, Bing Zhang, Haitao Yang
  • Patent number: 11464765
    Abstract: Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 11, 2022
    Assignee: SHANGHAITECH UNIVERSITY
    Inventors: Haitao Yang, Zhenming Jin, Xiuna Yang, Yao Zhao, Zihe Rao
  • Publication number: 20220017492
    Abstract: The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 20, 2022
    Inventors: Zihe RAO, Jun LI, Bing ZHANG, Haitao YANG
  • Publication number: 20210369696
    Abstract: Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 2, 2021
    Inventors: Haitao YANG, Zhenming JIN, Xiuna YANG, Yao ZHAO, Zihe RAO
  • Patent number: 9629864
    Abstract: Disclosed is a use of baicalin in the preparation of drugs for treating acute hemolytic uremic syndrome.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: April 25, 2017
    Assignees: HUBEI WUDANG ANIMAL PHARMACEUTICAL CO., LTD., JILIN UNIVERSITY, TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE
    Inventors: Xuming Deng, Zihe Rao, Jing Dong, Cheng Yang, Xiaodi Niu, Xuemei Li, Yutao Chen, Quan Wang, Dacheng Wang
  • Publication number: 20160361334
    Abstract: Provided is an application of baicalin in preparation of a drug for treating ricin poisoning. A Hela cytoprotection test and a mouse ricin poisoning model have verified the recovery effect of baicalin on ricin poisoning.
    Type: Application
    Filed: April 29, 2014
    Publication date: December 15, 2016
    Applicants: JILIN UNIVERSITY, INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Xuming DENG, Zihe RAO, Jing DONG, Xuemei LI, Yong ZHANG, Yutao CHEN, Jiazhang QIU
  • Publication number: 20160235777
    Abstract: Disclosed is a use of baicalin in the preparation of drugs for treating acute hemolytic uremic syndrome.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 18, 2016
    Applicants: HUBEI WUDANG ANIMAL PHARMACEUTICAL CO., LTD., JILIN UNIVERSITY, TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE
    Inventors: Xuming DENG, Zihe RAO, Jing DONG, Cheng YANG, Xiaodi NIU, Xuemei LI, Yutao CHEN, Quan WANG, Dacheng WANG
  • Patent number: 9017960
    Abstract: Present invention discloses the three-dimensional crystal structure of the N-terminus polypeptide of influenza virus polymerase subunit (PA_N of SEQ ID NO:7). PA_N of SEQ ID NO: 1 is residues 1—50 to 150-300 of influenza virus polymerase subunit PA. In the three-dimensional structure, at least 40% of atoms show the same atomic coordinates, compared to that listed in Table 1. Namely, in the three-dimensional structure of influenza virus polymerase subunit PA_N of SEQ ID NO: 7, 40% of atomic coordinates on carbon skeleton of residues of influenza virus polymerase subunit PA_N of SEQ ID NO: 7, show less than or equal to 1.7 ? of average variance, compared to the atomic coordinates listed in Table 1. Present invention also discloses the expression, purification, crystallization methods, and three-dimensional crystal structure of 256 residues in the N-terminus of influenza virus polymerase subunit PA, and applications of the crystal structure of SEQ ID NO: 7 on drug screening and designing.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: April 28, 2015
    Assignee: Institute of Biophysics Chinese Academy of Sciences
    Inventors: Yingfang Liu, Zihe Rao
  • Publication number: 20130046076
    Abstract: Present invention disclosed three-dimensional crystal structure of N-terminus polypeptide of influenza virus polymerase subunit (PA_N). PA_N is residues 1˜50 to 150˜300 of influenza virus polymerase subunit PA. In three-dimensional structure, at least 40% of atoms showed same atomic coordinates, compared to that listed in Table. In other words, in three-dimensional structure of influenza virus polymerase subunit PA_N, 40% of atomic coordinates on carbon skeleton of residues of influenza virus polymerase subunit PA_N, showed less than or equal to 1.7 ? of average variance, compared to the atomic coordinates listed in Table1. Present invention also disclosed the expression, purification, crystallization methods, and three-dimensional crystal structure of 256 residues in the N-terminus of influenza virus polymerase subunit PA, and applications of the crystal structure on drug screening and designing.
    Type: Application
    Filed: February 3, 2010
    Publication date: February 21, 2013
    Applicant: Institute of Biophysics Chinese Academy of Sciences
    Inventors: Yingfang Liu, Zihe Rao
  • Publication number: 20090232900
    Abstract: The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation of anthracycline antitumor antibiotics for injection. The anthracycline antitumor antibiotics and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly homogeneous particle size.
    Type: Application
    Filed: June 24, 2005
    Publication date: September 17, 2009
    Applicant: Institute of Biophysics, Chinese Academy of Sciences
    Inventors: Wei Liang, Ning Tang, Chunling Zhang, Zihe Rao
  • Patent number: 7304057
    Abstract: This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: December 4, 2007
    Assignee: Institute of Pharmacology and Toxicology Accademy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Aihua Nie, Beifen Shen, Lili Wang, Wuhong Pei, Junhai Xiao, Songcheng Yang, Liuhong Yun, Hongying Liu, Cuiling Shu, Hongxia Wang, Zihe Rao
  • Publication number: 20050130958
    Abstract: This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases.
    Type: Application
    Filed: December 5, 2002
    Publication date: June 16, 2005
    Inventors: Song Li, Aihua Nie, Beifen Shen, Lili Wang, Wuhong Pei, Junhai Xiao, Songcheng Yang, Liuhong Yun, Hongying Liu, Cuiling Shu, Hongxia Wang, Zihe Rao